<?xml version="1.0" encoding="utf-8" standalone="no"?>
<billStatus>
  <version>3.0.0</version>
  <bill>
    <number>4348</number>
    <updateDate>2022-12-29T18:33:46Z</updateDate>
    <updateDateIncludingText>2022-12-29T18:33:46Z</updateDateIncludingText>
    <originChamber>Senate</originChamber>
    <type>S</type>
    <introducedDate>2022-05-26</introducedDate>
    <congress>117</congress>
    <committees>
      <item>
        <systemCode>sshr00</systemCode>
        <name>Health, Education, Labor, and Pensions Committee</name>
        <chamber>Senate</chamber>
        <type>Standing</type>
        <activities>
          <item>
            <name>Reported by</name>
            <date>2022-07-13T15:11:36Z</date>
          </item>
          <item>
            <name>Markup by</name>
            <date>2022-06-14T14:00:02Z</date>
          </item>
          <item>
            <name>Referred to</name>
            <date>2022-05-26T20:49:25Z</date>
          </item>
        </activities>
      </item>
    </committees>
    <relatedBills>
      <item>
        <title>Reducing Animal Testing Act</title>
        <congress>117</congress>
        <number>4288</number>
        <type>S</type>
        <latestAction>
          <actionDate>2022-05-19</actionDate>
          <text>Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</text>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Related bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
      <item>
        <title>Biologics Market Transparency Act of 2022</title>
        <congress>117</congress>
        <number>7035</number>
        <type>HR</type>
        <latestAction>
          <actionDate>2022-03-10</actionDate>
          <text>Referred to the Subcommittee on Health.</text>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Related bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
      <item>
        <title>To amend the Orphan Drug Act to reauthorize a program of grants and contracts for the development of drugs for rare diseases and conditions (commonly referred to as "orphan drugs").</title>
        <congress>117</congress>
        <number>7640</number>
        <type>HR</type>
        <latestAction>
          <actionDate>2022-05-03</actionDate>
          <text>Referred to the House Committee on Energy and Commerce.</text>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Related bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
      <item>
        <title>To amend the Federal Food, Drug, and Cosmetic Act to reauthorize the Critical Path Public-Private Partnerships.</title>
        <congress>117</congress>
        <number>7658</number>
        <type>HR</type>
        <latestAction>
          <actionDate>2022-05-03</actionDate>
          <text>Referred to the House Committee on Energy and Commerce.</text>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Related bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
      <item>
        <title>To amend the Federal Food, Drug, and Cosmetic Act to reauthorize the authority to grant certain exemptions, and for other purposes.</title>
        <congress>117</congress>
        <number>7679</number>
        <type>HR</type>
        <latestAction>
          <actionDate>2022-05-06</actionDate>
          <text>Referred to the House Committee on Energy and Commerce.</text>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Related bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
      <item>
        <title>Better ODDS To Reduce Diversion Act of 2021</title>
        <congress>117</congress>
        <number>2628</number>
        <type>S</type>
        <latestAction>
          <actionDate>2021-08-05</actionDate>
          <text>Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</text>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Related bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
      <item>
        <title>FDA Modernization Act of 2021</title>
        <congress>117</congress>
        <number>2952</number>
        <type>S</type>
        <latestAction>
          <actionDate>2021-10-07</actionDate>
          <text>Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</text>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Related bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
      <item>
        <title>A bill to amend the Federal Food, Drug, and Cosmetic Act to reauthorize the Critical Path Public-Private Partnerships.</title>
        <congress>117</congress>
        <number>4152</number>
        <type>S</type>
        <latestAction>
          <actionDate>2022-05-05</actionDate>
          <text>Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</text>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Related bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
      <item>
        <title>Biologics Market Transparency Act of 2022</title>
        <congress>117</congress>
        <number>4302</number>
        <type>S</type>
        <latestAction>
          <actionDate>2022-05-25</actionDate>
          <text>Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Sponsor introductory remarks on measure: CR S2709)</text>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Related bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
      <item>
        <title>Interchangeable Biologics Clarity Act</title>
        <congress>117</congress>
        <number>4303</number>
        <type>S</type>
        <latestAction>
          <actionDate>2022-05-25</actionDate>
          <text>Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Sponsor introductory remarks on measure: CR S2709-2710)</text>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Related bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
      <item>
        <title>Hatch-Waxman Improvement Act of 2022</title>
        <congress>117</congress>
        <number>4378</number>
        <type>S</type>
        <latestAction>
          <actionDate>2022-06-13</actionDate>
          <text>Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</text>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Related bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
      <item>
        <title>Modernizing the Accelerated Approval Pathway Act of 2022</title>
        <congress>117</congress>
        <number>4446</number>
        <type>S</type>
        <latestAction>
          <actionDate>2022-06-22</actionDate>
          <text>Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Sponsor introductory remarks on measure: CR S3077-3078)</text>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Related bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
      <item>
        <title>FDASRA Act of 2022</title>
        <congress>117</congress>
        <number>4535</number>
        <type>S</type>
        <latestAction>
          <actionDate>2022-07-14</actionDate>
          <text>Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</text>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Related bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
      <item>
        <title>FDA Modernization Act 2.0</title>
        <congress>117</congress>
        <number>5002</number>
        <type>S</type>
        <latestAction>
          <actionDate>2022-09-29</actionDate>
          <text>Held at the desk.</text>
          <actionTime>18:51:15</actionTime>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Related bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
      <item>
        <title>Small Business Establishment Registration Waiver Act</title>
        <congress>117</congress>
        <number>9329</number>
        <type>HR</type>
        <latestAction>
          <actionDate>2022-11-18</actionDate>
          <text>Referred to the Subcommittee on Health.</text>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Related bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
    </relatedBills>
    <actions>
      <item>
        <actionDate>2022-07-13</actionDate>
        <sourceSystem>
          <name>Senate</name>
        </sourceSystem>
        <text>Placed on Senate Legislative Calendar under General Orders. Calendar No. 444.</text>
        <type>Calendars</type>
      </item>
      <item>
        <actionDate>2022-07-13</actionDate>
        <committees>
          <item>
            <systemCode>sshr00</systemCode>
            <name>Health, Education, Labor, and Pensions Committee</name>
          </item>
        </committees>
        <sourceSystem>
          <name>Senate</name>
        </sourceSystem>
        <text>Committee on Health, Education, Labor, and Pensions. Reported by Senator Murray with an amendment in the nature of a substitute. Without written report.</text>
        <type>Committee</type>
      </item>
      <item>
        <actionDate>2022-07-13</actionDate>
        <text>Committee on Health, Education, Labor, and Pensions. Reported by Senator Murray with an amendment in the nature of a substitute. Without written report.</text>
        <type>Committee</type>
        <actionCode>14000</actionCode>
        <sourceSystem>
          <code>9</code>
          <name>Library of Congress</name>
        </sourceSystem>
        <committees>
          <item>
            <systemCode>sshr00</systemCode>
            <name>Health, Education, Labor, and Pensions Committee</name>
          </item>
        </committees>
      </item>
      <item>
        <actionDate>2022-06-14</actionDate>
        <committees>
          <item>
            <systemCode>sshr00</systemCode>
            <name>Health, Education, Labor, and Pensions Committee</name>
          </item>
        </committees>
        <sourceSystem>
          <name>Senate</name>
        </sourceSystem>
        <text>Committee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment in the nature of a substitute favorably.</text>
        <type>Committee</type>
      </item>
      <item>
        <actionDate>2022-05-26</actionDate>
        <committees>
          <item>
            <systemCode>sshr00</systemCode>
            <name>Health, Education, Labor, and Pensions Committee</name>
          </item>
        </committees>
        <sourceSystem>
          <name>Senate</name>
        </sourceSystem>
        <text>Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</text>
        <type>IntroReferral</type>
      </item>
      <item>
        <actionDate>2022-05-26</actionDate>
        <text>Introduced in Senate</text>
        <type>IntroReferral</type>
        <actionCode>10000</actionCode>
        <sourceSystem>
          <code>9</code>
          <name>Library of Congress</name>
        </sourceSystem>
      </item>
    </actions>
    <sponsors>
      <item>
        <bioguideId>M001111</bioguideId>
        <fullName>Sen. Murray, Patty [D-WA]</fullName>
        <firstName>Patty</firstName>
        <lastName>Murray</lastName>
        <party>D</party>
        <state>WA</state>
        <identifiers>
          <bioguideId>M001111</bioguideId>
        </identifiers>
        <isByRequest>N</isByRequest>
      </item>
    </sponsors>
    <cosponsors>
      <item>
        <bioguideId>B001135</bioguideId>
        <fullName>Sen. Burr, Richard [R-NC]</fullName>
        <firstName>Richard</firstName>
        <lastName>Burr</lastName>
        <party>R</party>
        <state>NC</state>
        <identifiers>
          <bioguideId>B001135</bioguideId>
        </identifiers>
        <middleName>Mauze</middleName>
        <sponsorshipDate>2022-05-26</sponsorshipDate>
        <isOriginalCosponsor>True</isOriginalCosponsor>
      </item>
    </cosponsors>
    <cboCostEstimates>
      <item>
        <pubDate>2022-07-21T14:30:00Z</pubDate>
        <title>Estimated Direct Spending and Revenue Effects of S. 4348, the Food and Drug Administration Safety and Landmark Advancements Act of 2022</title>
        <url>https://www.cbo.gov/publication/58318</url>
      </item>
    </cboCostEstimates>
    <policyArea>
      <name>Health</name>
    </policyArea>
    <subjects>
      <legislativeSubjects>
        <item>
          <name>Administrative law and regulatory procedures</name>
        </item>
        <item>
          <name>Administrative remedies</name>
        </item>
        <item>
          <name>Allergies</name>
        </item>
        <item>
          <name>Animal protection and human-animal relationships</name>
        </item>
        <item>
          <name>Business records</name>
        </item>
        <item>
          <name>Child health</name>
        </item>
        <item>
          <name>Congressional oversight</name>
        </item>
        <item>
          <name>Cosmetics and personal care</name>
        </item>
        <item>
          <name>Department of Health and Human Services</name>
        </item>
        <item>
          <name>Drug safety, medical device, and laboratory regulation</name>
        </item>
        <item>
          <name>Drug therapy</name>
        </item>
        <item>
          <name>Drug trafficking and controlled substances</name>
        </item>
        <item>
          <name>Employee hiring</name>
        </item>
        <item>
          <name>Executive agency funding and structure</name>
        </item>
        <item>
          <name>Federal preemption</name>
        </item>
        <item>
          <name>Food and Drug Administration (FDA)</name>
        </item>
        <item>
          <name>Food industry and services</name>
        </item>
        <item>
          <name>Food supply, safety, and labeling</name>
        </item>
        <item>
          <name>Government employee pay, benefits, personnel management</name>
        </item>
        <item>
          <name>Government information and archives</name>
        </item>
        <item>
          <name>Government studies and investigations</name>
        </item>
        <item>
          <name>Hazardous wastes and toxic substances</name>
        </item>
        <item>
          <name>Health technology, devices, supplies</name>
        </item>
        <item>
          <name>Hearing, speech, and vision care</name>
        </item>
        <item>
          <name>Industrial facilities</name>
        </item>
        <item>
          <name>Licensing and registrations</name>
        </item>
        <item>
          <name>Manufacturing</name>
        </item>
        <item>
          <name>Medical research</name>
        </item>
        <item>
          <name>Medical tests and diagnostic methods</name>
        </item>
        <item>
          <name>Nutrition and diet</name>
        </item>
        <item>
          <name>Prescription drugs</name>
        </item>
        <item>
          <name>Product safety and quality</name>
        </item>
        <item>
          <name>Public-private cooperation</name>
        </item>
        <item>
          <name>Small business</name>
        </item>
        <item>
          <name>Solid waste and recycling</name>
        </item>
        <item>
          <name>State and local government operations</name>
        </item>
        <item>
          <name>User charges and fees</name>
        </item>
      </legislativeSubjects>
      <policyArea>
        <name>Health</name>
      </policyArea>
    </subjects>
    <summaries>
      <summary>
        <versionCode>00</versionCode>
        <actionDate>2022-05-26</actionDate>
        <actionDesc>Introduced in Senate</actionDesc>
        <updateDate>2022-09-06T15:13:27Z</updateDate>
        <text>
          <![CDATA[ <p><strong>Food and Drug Administration Safety and Landmark Advancements Act of 2022 or the FDASLA Act of 2022</strong></p> <p>This bill modifies Food and Drug Administration (FDA) authority to collect certain fees. It also expands FDA authority to regulate certain products, including cosmetics.</p> <p>Among other provisions, the bill</p> <ul> <li>reauthorizes FDA authority to collect certain fees related to drugs, medical devices, and biosimilar biological products and modifies such fees, including the base fee amounts;</li> <li>establishes that certain requirements related to obtaining market approval for a new drug or a biosimilar may be satisfied using alternatives to animal testing, such as in vitro tests;</li> <li>authorizes the FDA to require that certain drugs be dispensed with a safe disposal system even if the system does not render a drug nonretrievable (current law requires such a system to render the drug nonretrievable); </li> <li>establishes time lines for the FDA to respond to requests to determine whether a drug is a therapeutic equivalent to an approved drug;</li> <li>modifies the accelerated process for approving products for a serious or life-threatening disease or condition and establishes an intra-agency coordinating council to ensure consistent and appropriate use of the process;</li> <li>requires additional regulation of cosmetics, including by requiring manufacturers to register manufacturing facilities and each cosmetic product with the FDA;</li> <li>requires dietary supplement manufacturers to provide to the FDA certain information, including a list of all ingredients, about each dietary supplement that it markets; and</li> <li>requires an in vitro clinical test to receive FDA premarket approval or a technology certification (or be otherwise exempted) before being introduced into interstate commerce. </li> </ul>]]>
        </text>
      </summary>
      <summary>
        <versionCode>25</versionCode>
        <actionDate>2022-07-13</actionDate>
        <actionDesc>Reported to Senate</actionDesc>
        <updateDate>2022-09-09T14:06:34Z</updateDate>
        <text>
          <![CDATA[ <p><strong>Food and Drug Administration Safety and Landmark Advancements Act of 2022 or the FDASLA Act of 2022</strong></p> <p>This bill modifies Food and Drug Administration (FDA) authority to collect certain fees. It also expands FDA authority to regulate certain products, including cosmetics.</p> <p>Among other provisions, the bill</p> <ul> <li>reauthorizes FDA authority to collect certain fees related to drugs, medical devices, and biosimilar biological products and modifies such fees, including the base fee amounts;</li> <li>establishes that certain requirements related to obtaining market approval for a new drug or a biosimilar may be satisfied using alternatives to animal testing, such as in vitro tests;</li> <li>authorizes the FDA to require that certain drugs be dispensed with a safe disposal system even if the system does not render a drug nonretrievable (current law requires such a system to render the drug nonretrievable); </li> <li>establishes time lines for the FDA to respond to requests to determine whether a drug is a therapeutic equivalent to an approved drug;</li> <li>modifies the accelerated process for approving products for a serious or life-threatening disease or condition and establishes an intra-agency coordinating council to ensure consistent and appropriate use of the process;</li> <li>requires additional regulation of cosmetics, including by requiring manufacturers to register manufacturing facilities and each cosmetic product with the FDA;</li> <li>requires dietary supplement manufacturers to provide to the FDA certain information, including a list of all ingredients, about each dietary supplement that it markets; </li> <li>requires an in vitro clinical test to receive FDA premarket approval or a technology certification (or be otherwise exempted) before being introduced into interstate commerce; and</li> <li>requires the FDA to temporarily relax certain premarket requirements for a manufacturer that intends to market a new infant formula. </li> </ul>]]>
        </text>
      </summary>
    </summaries>
    <title>FDASLA Act of 2022</title>
    <titles>
      <item>
        <titleType>Display Title</titleType>
        <title>FDASLA Act of 2022</title>
      </item>
      <item>
        <titleType>Short Title(s) as Reported to Senate for portions of this bill</titleType>
        <title>Prescription Drug User Fee Amendments of 2022</title>
        <chamberCode>S</chamberCode>
        <chamberName>Senate</chamberName>
        <billTextVersionName>Reported to Senate</billTextVersionName>
        <billTextVersionCode>RS</billTextVersionCode>
      </item>
      <item>
        <titleType>Short Title(s) as Reported to Senate for portions of this bill</titleType>
        <title>Medical Device User Fee Amendments of 2022</title>
        <chamberCode>S</chamberCode>
        <chamberName>Senate</chamberName>
        <billTextVersionName>Reported to Senate</billTextVersionName>
        <billTextVersionCode>RS</billTextVersionCode>
      </item>
      <item>
        <titleType>Short Title(s) as Reported to Senate for portions of this bill</titleType>
        <title>Biosimilar User Fee Amendments of 2022</title>
        <chamberCode>S</chamberCode>
        <chamberName>Senate</chamberName>
        <billTextVersionName>Reported to Senate</billTextVersionName>
        <billTextVersionCode>RS</billTextVersionCode>
      </item>
      <item>
        <titleType>Short Title(s) as Reported to Senate for portions of this bill</titleType>
        <title>Food and Drug Administration Safety and Landmark Advancements Act of 2022</title>
        <chamberCode>S</chamberCode>
        <chamberName>Senate</chamberName>
        <billTextVersionName>Reported to Senate</billTextVersionName>
        <billTextVersionCode>RS</billTextVersionCode>
      </item>
      <item>
        <titleType>Short Title(s) as Reported to Senate for portions of this bill</titleType>
        <title>Modernization of Cosmetics Regulation Act of 2022</title>
        <chamberCode>S</chamberCode>
        <chamberName>Senate</chamberName>
        <billTextVersionName>Reported to Senate</billTextVersionName>
        <billTextVersionCode>RS</billTextVersionCode>
      </item>
      <item>
        <titleType>Short Title(s) as Reported to Senate for portions of this bill</titleType>
        <title>Verifying Accurate Leading-edge IVCT Development Act of 2022</title>
        <chamberCode>S</chamberCode>
        <chamberName>Senate</chamberName>
        <billTextVersionName>Reported to Senate</billTextVersionName>
        <billTextVersionCode>RS</billTextVersionCode>
      </item>
      <item>
        <titleType>Short Title(s) as Reported to Senate</titleType>
        <title>FDASLA Act of 2022</title>
        <chamberCode>S</chamberCode>
        <chamberName>Senate</chamberName>
        <billTextVersionName>Reported to Senate</billTextVersionName>
        <billTextVersionCode>RS</billTextVersionCode>
      </item>
      <item>
        <titleType>Short Title(s) as Reported to Senate</titleType>
        <title>Food and Drug Administration Safety and Landmark Advancements Act of 2022</title>
        <chamberCode>S</chamberCode>
        <chamberName>Senate</chamberName>
        <billTextVersionName>Reported to Senate</billTextVersionName>
        <billTextVersionCode>RS</billTextVersionCode>
      </item>
      <item>
        <titleType>Short Title(s) as Reported to Senate for portions of this bill</titleType>
        <title>Generic Drug User Fee Amendments of 2022</title>
        <chamberCode>S</chamberCode>
        <chamberName>Senate</chamberName>
        <billTextVersionName>Reported to Senate</billTextVersionName>
        <billTextVersionCode>RS</billTextVersionCode>
      </item>
      <item>
        <titleType>Short Title(s) as Reported to Senate for portions of this bill</titleType>
        <title>VALID Act of 2022</title>
        <chamberCode>S</chamberCode>
        <chamberName>Senate</chamberName>
        <billTextVersionName>Reported to Senate</billTextVersionName>
        <billTextVersionCode>RS</billTextVersionCode>
      </item>
      <item>
        <titleType>Short Title(s) as Introduced for portions of this bill</titleType>
        <title>Generic Drug User Fee Amendments of 2022</title>
        <billTextVersionName>Introduced in Senate</billTextVersionName>
        <billTextVersionCode>IS</billTextVersionCode>
      </item>
      <item>
        <titleType>Short Title(s) as Introduced</titleType>
        <title>FDASLA Act of 2022</title>
        <billTextVersionName>Introduced in Senate</billTextVersionName>
        <billTextVersionCode>IS</billTextVersionCode>
      </item>
      <item>
        <titleType>Short Title(s) as Introduced</titleType>
        <title>Food and Drug Administration Safety and Landmark Advancements Act of 2022</title>
        <billTextVersionName>Introduced in Senate</billTextVersionName>
        <billTextVersionCode>IS</billTextVersionCode>
      </item>
      <item>
        <titleType>Short Title(s) as Introduced for portions of this bill</titleType>
        <title>VALID Act of 2022</title>
        <billTextVersionName>Introduced in Senate</billTextVersionName>
        <billTextVersionCode>IS</billTextVersionCode>
      </item>
      <item>
        <titleType>Short Title(s) as Introduced for portions of this bill</titleType>
        <title>Food and Drug Administration Safety and Landmark Advancements Act of 2022</title>
        <billTextVersionName>Introduced in Senate</billTextVersionName>
        <billTextVersionCode>IS</billTextVersionCode>
      </item>
      <item>
        <titleType>Short Title(s) as Introduced for portions of this bill</titleType>
        <title>Modernization of Cosmetics Regulation Act of 2022</title>
        <billTextVersionName>Introduced in Senate</billTextVersionName>
        <billTextVersionCode>IS</billTextVersionCode>
      </item>
      <item>
        <titleType>Official Title as Introduced</titleType>
        <title>A bill to amend the Federal Food, Drug, and Cosmetic Act to revise and extend the user-fee programs for prescription drugs, medical devices, generic drugs, and biosimilar biological products, and for other purposes.</title>
        <billTextVersionName>Introduced in Senate</billTextVersionName>
        <billTextVersionCode>IS</billTextVersionCode>
      </item>
    </titles>
    <textVersions>
      <item>
        <type>Reported to Senate</type>
        <date>2022-07-13T04:00:00Z</date>
        <formats>
          <item>
            <url>https://www.govinfo.gov/content/pkg/BILLS-117s4348rs/xml/BILLS-117s4348rs.xml</url>
          </item>
        </formats>
      </item>
      <item>
        <type>Introduced in Senate</type>
        <date>2022-05-26T04:00:00Z</date>
        <formats>
          <item>
            <url>https://www.govinfo.gov/content/pkg/BILLS-117s4348is/xml/BILLS-117s4348is.xml</url>
          </item>
        </formats>
      </item>
      <item>
        <date/>
        <formats/>
        <type/>
      </item>
    </textVersions>
    <latestAction>
      <actionDate>2022-07-13</actionDate>
      <text>Placed on Senate Legislative Calendar under General Orders. Calendar No. 444.</text>
    </latestAction>
  </bill>
  <dublinCore xmlns:dc="http://purl.org/dc/elements/1.1/">
    <dc:format>text/xml</dc:format>
    <dc:language>EN</dc:language>
    <dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
    <dc:contributor>Congressional Research Service, Library of Congress</dc:contributor>
    <dc:description>This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.</dc:description>
  </dublinCore>
</billStatus>
